EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Prevalence of hepatitis B, tetanus, hepatitis A, human immunodeficiency virus and feasibility of vaccine delivery among injecting drug users in Bangkok, Thailand, 2003-2005



Prevalence of hepatitis B, tetanus, hepatitis A, human immunodeficiency virus and feasibility of vaccine delivery among injecting drug users in Bangkok, Thailand, 2003-2005



Addiction 103(10): 1687-1695



Objectives To estimate the prevalence of hepatitis B virus (HBV), tetanus, hepatitis A virus (HAV) and human immunodeficiency virus (HIV) in injecting drug users (IDUs), risk factors associated with infection and the feasibility of HBV vaccine delivery in HBV seronegatives. Methods Cross-sectional seroprevalence survey of 1535 IDUs recruited from 17 Bangkok Metropolitan Administration (BMA) methadone clinics and HBV vaccination of seronegatives. Results Prevalence of antibody to HBV, tetanus, HAV and HIV was 87.8%, 68.1%, 60.2% and 35.9%, respectively. Prevalence of HBV and HAV increased with increasing age; prevalence of tetanus decreased with increasing age. Being HIV seropositive was related inversely to income and being tetanus seronegative. Of the 189 HBV seronegative IDUs, 81.0% completed the vaccine series. IDUs with HIV had a 6.5-fold odds of vaccine non-response. Conclusions These data underscore the need for, and feasibility of, vaccine delivery in this population and support targeting efforts at high-risk age groups.

(PDF emailed within 0-6 h: $19.90)

Accession: 032939295

Download citation: RISBibTeXText

PMID: 18705685

DOI: 10.1111/j.1360-0443.2008.02303.x



Related references

Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999-2003. Addiction 104(2): 235-242, 2009

The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. International Journal of Epidemiology 32(5): 708-714, 2003

Prevalence of human immunodeficiency virus and hepatitis C virus, and associated factors among injecting drug users in Catalonia. Enfermedades Infecciosas Y Microbiologia Clinica 28(4): 236-238, 2010

Feasibility of an HIV-1 vaccine efficacy trial among injecting drug users in Bangkok, Thailand. ELEVENTH INTERNATIONAL CONFERENCE ON AIDS [Author] Eleventh International Conference on AIDS, Vol Two One world: One hope : 34-35, 1996

Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. American Journal of Epidemiology 155(2): 159-168, 2002

Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. American Journal of Epidemiology 157(5): 467-471, March 1, 2003

History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. International Journal of Epidemiology 26(6): 1359-1366, 1998

Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysis. Addiction 105(2): 311-318, 2010

The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Addiction 107(3): 614-623, 2012

Coinfection by human immunodeficiency virus, hepatitis B virus and hepatitis C virus in injecting drug users. Journal of the Indian Medical Association 107(3): 144, 146-7, 2009

Infection disclosure in the injecting dyads of Hungarian and Lithuanian injecting drug users who self-reported being infected with hepatitis C virus or human immunodeficiency virus. Scandinavian Journal of Infectious Diseases 43(1): 32-42, 2011

Differential seroprevalences of hepatitis C virus, hepatitis B virus and human immunodeficiency virus among intravenous drug users, commercial sex workers and patients with sexually transmitted diseases in Chiang Mai, Thailand. Hepatology Research 27(1): 6-12, September, 2003

Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 105(5): 844-859, 2010

Prevalence and correlates of infection with human immunodeficiency virus, hepatitis B virus, and hepatitis C virus among drug users in Italy: a cross-sectional study. Scandinavian Journal of Infectious Diseases 41(6-7): 520-523, 2010

A study on the prevalence rates of human immunodeficiency virus, hepatitis B virus and hepatitis C virus infections in intravenous drug users. Zhonghua Liu Xing Bing Xue Za Zhi 27(9): 777-779, 2007